Expert Interview
Discussing Amgen's Phase 3 trials for Uplizna (Inebilizumab-CDON), which has shown to improve myasthenia gravis symptoms in acetylcholine receptor-antibody positive patients.
Ticker(s): AMGNInstitution: Private Practice
- Clinical neurophysiologist in private practice.
- Currently manages 80 patients with multiple sclerosis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
